+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Lung Cancer Genomic Testing Market by Technology, Sample Type, Panel Type, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 186 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5925112
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Lung Cancer Genomic Testing Market grew from USD 1.01 billion in 2023 to USD 1.07 billion in 2024. It is expected to continue growing at a CAGR of 8.00%, reaching USD 1.73 billion by 2030.

Lung cancer genomic testing refers to the process of analyzing the genetic mutations and alterations in lung cancer cells, enabling personalized treatment approaches. This testing is critical for identifying actionable mutations and selecting targeted therapies, significantly impacting patient outcomes. The necessity of genomic testing is underscored by the diverse mutations observed in lung cancer cases, which influence treatment efficacy; hence, it is applied extensively in advanced healthcare settings, primarily within hospitals and cancer research centers. End-use scope extends to personalized medicine, clinical trials, and tailored therapeutic developments. Market growth is chiefly influenced by rising lung cancer prevalence, expanding precision medicine adoption, and advancements in genomic technologies. The burgeoning emergence of non-invasive testing methods holds great promise, as does the integration of AI in genomic analysis, offering substantial market opportunities for innovation. However, market expansion faces challenges such as high costs, limited availability in developing regions, and the need for skilled personnel to interpret complex data. Regulatory and ethical issues further complicate widespread adoption. Recommended strategies include enhancing affordability, expanding regional access through partnerships, and investing in AI and machine learning for data interpretation to streamline clinical decisions. Potential areas of innovation include the development of multi-gene panel testing, improvements in bioinformatics tools, and leveraging CRISPR technology for precision gene editing in research and treatment scenarios. The market dynamic is characterized by rapid technological advancements, an increased focus on personalized treatment solutions, and significant investments from biotech firms. The competitive landscape requires continuous R&D to maintain an edge. A focus on scalable solutions and collaborations with healthcare providers can play a pivotal role in capturing unmet needs and capitalizing on emerging trends in the lung cancer genomic testing market.

Understanding Market Dynamics in the Lung Cancer Genomic Testing Market

The Lung Cancer Genomic Testing Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising number of cancer incidences across the world
    • Government initiatives to expand access to lung cancer treatment
    • Growing number of research activities and collaborations to expand cancer care and prevention
  • Market Restraints
    • High cost of genetic testing services and the lack of reimbursement
  • Market Opportunities
    • Advancements in next-generation genome sequencing
    • Inclination toward adoption of personalized medicine and biomarker testing
  • Market Challenges
    • Stringent regulations concerning genetic and molecular testing

Exploring Porter’s Five Forces for the Lung Cancer Genomic Testing Market

Porter’s Five Forces framework further strengthens the insights of the Lung Cancer Genomic Testing Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Lung Cancer Genomic Testing Market

External macro-environmental factors deeply influence the performance of the Lung Cancer Genomic Testing Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Lung Cancer Genomic Testing Market

The Lung Cancer Genomic Testing Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Lung Cancer Genomic Testing Market

The Lung Cancer Genomic Testing Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Lung Cancer Genomic Testing Market

The Lung Cancer Genomic Testing Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lung Cancer Genomic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Admera Health, Agilent Technologies, Inc., BGI, CD Genomics, CeGaT GmbH, Centogene N.V., F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, NeoGenomics Laboratories, OncoDNA, OPKO Health, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., and Veracyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Lung Cancer Genomic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Technology
    • Fluorescence In Situ Hybridization
    • Next-Generation Sequencing
    • Polymerase Chain Reaction
  • Sample Type
    • Liquid Biopsy
    • Tissue Biopsy
  • Panel Type
    • Multi-Gene Panel
    • Single-Gene Panel
  • End User
    • Diagnostic Laboratories
    • Hospitals/Clinics
    • Research Organization
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising number of cancer incidences across the world
5.1.1.2. Government initiatives to expand access to lung cancer treatment
5.1.1.3. Growing number of research activities and collaborations to expand cancer care and prevention
5.1.2. Restraints
5.1.2.1. High cost of genetic testing services and the lack of reimbursement
5.1.3. Opportunities
5.1.3.1. Advancements in next-generation genome sequencing
5.1.3.2. Inclination toward adoption of personalized medicine and biomarker testing
5.1.4. Challenges
5.1.4.1. Stringent regulations concerning genetic and molecular testing
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Lung Cancer Genomic Testing Market, by Technology
6.1. Introduction
6.2. Fluorescence In Situ Hybridization
6.3. Next-Generation Sequencing
6.4. Polymerase Chain Reaction
7. Lung Cancer Genomic Testing Market, by Sample Type
7.1. Introduction
7.2. Liquid Biopsy
7.3. Tissue Biopsy
8. Lung Cancer Genomic Testing Market, by Panel Type
8.1. Introduction
8.2. Multi-Gene Panel
8.3. Single-Gene Panel
9. Lung Cancer Genomic Testing Market, by End User
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals/Clinics
9.4. Research Organization
10. Americas Lung Cancer Genomic Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Lung Cancer Genomic Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Lung Cancer Genomic Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. LUNG CANCER GENOMIC TESTING MARKET RESEARCH PROCESS
FIGURE 2. LUNG CANCER GENOMIC TESTING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2023 VS 2030 (%)
FIGURE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. LUNG CANCER GENOMIC TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. LUNG CANCER GENOMIC TESTING MARKET DYNAMICS
TABLE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MULTI-GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SINGLE-GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS/CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 26. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 35. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 36. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 37. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 39. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 40. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 41. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 52. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 58. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 59. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 61. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 62. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 63. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 70. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 71. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 93. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 94. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 95. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 105. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 107. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 108. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 111. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 112. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 115. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 116. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 119. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 120. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 123. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 124. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 130. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 131. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 132. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 143. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 144. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 147. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 148. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 150. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 151. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 152. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 161. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 167. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 168. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 179. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 180. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PANEL TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2023
TABLE 190. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Lung Cancer Genomic Testing Market, which are profiled in this report, include:
  • Abbott Laboratories
  • Admera Health
  • Agilent Technologies, Inc.
  • BGI
  • CD Genomics
  • CeGaT GmbH
  • Centogene N.V.
  • F. Hoffmann-La Roche AG
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories
  • OncoDNA
  • OPKO Health, Inc.
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Thermo Fisher Scientific, Inc.
  • Veracyte, Inc.

Methodology

Loading
LOADING...

Table Information